18 June 2019
The importance of patient-centric sampling: unique Coffee Chat from expert pharmaceutical and CRO professionals

Bioanalysis Zone showcases the first ever Coffee Chat; a unique series featuring key experts from the pharmaceutical and CRO industries, offering perspectives on patient-centric sampling.

Bioanalysis Zone is delighted to offer its members unique access to an informal and educational discussion centered on this new type of workflow that benefits the patient.

The Coffee Chat, hosted by Naamah Maundrell (Bioanalysis Zone), comprises conversations between three experts who have a passion for patient-centric sampling: Stephanie Cape (Covance), Shane Needham (Alturas Analytics) and Melanie Anderson (Merck). Key discussion topics that are explored include: what is patient-centric sampling, how patient-centric sampling has evolved, what hurdles remain for implementation and what can we expect in the next 5—10 years?

During the Coffee Chat, Shane Needham commented: “This is a good opportunity for the patient to be the consumer and the consumer to be patient – and they will drive where this [patient-centric sampling] goes!”

Bioanalysis Zone would also like to take this opportunity to thank the speakers, as well as the sponsors of this Coffee Chat: Alturas Analytics and Covance.

The Coffee Chat can be viewed on Bioanalysis Zone HERE. For any inquiries email Naamah Maundrell, Senior Editor of Bioanalysis Zone, at 

About Bioanalysis Zone 

Since launching in 2011, Bioanalysis Zone has attracted over 11,000 active members from the global bioanalytical community, representing the pharmaceutical, biotech and CRO industries, along with academia and healthcare. Each month, thousands of members visit the site to read industry news, peer-reviewed research, exclusive interviews, webinars and commentaries. Join the Bioanalysis Zone Twitter and LinkedIn group for updates.

About Future Science Group

Founded in 2001, FSG is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG’s portfolio consists of three imprints, Future Medicine, Future Science and Newlands Press, publishing both eBooks and journals. In addition to this core publishing business, FSG develops specialist knowledge networks and content hubs, enabling professionals to easily connect and collaborate with their peers in niche scientific fields.

 FSG currently publishes 34 peer-reviewed journals as well as 8 knowledge networks and content hubs across a wide range of therapy area and scientific fields. Key journals include Future Microbiology, Future Oncology and the Journal of Comparative Effectiveness Research, alongside sites such as Infectious Diseases Hub, Oncology Central and The Evidence Base.

The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.

© 2019 Future Science Group

Unitec House, 2 Albert Place,

London, N3 1QB, UK

Tel: +44 (0)20 8371 6090

  • LinkedIn - White Circle
  • Facebook - White Circle
  • Twitter - White Circle
  • YouTube - White Circle